Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent Dosages-Reference-Cited by-同舟云学术

Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent Dosages

Published:2001-08 Issue:2 Volume:82 Page:323-328
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Rose Peter G.,Hawthorne Maxson Jan,Fusco Nancy,Mossbruger Kim,Rodriguez Michael

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference12 articles.

1. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation;Muggia;J Clin Oncol,1997

2. Phase II study of stealth liposomal doxorubicin (Doxil) in platinum and paclitaxel refractory epithelial ovarian cancer;Gordon;J Clin Oncol,2000

3. Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer;Gordon;Proc Am Soc Clin Oncol,2000

4. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum;Markman;Gynecol Oncol,2000

5. A retrospective analysis of the clinical utility of liposomal doxorubicin in recurrent ovarian cancer (ROC);Campos;Proc Am Soc Clin Oncol,1999

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer;Cancer Medicine;2023-05-15

2. Efficacy of non‑platinum chemotherapy in platinum‑resistant ovarian cancer: a meta‑analysis;Malignant tumours;2022-04-08

3. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial;Journal of Gynecologic Oncology;2021

4. Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine;Journal of Obstetrics and Gynaecology Research;2020-11-04

5. Management of cytotoxic chemotherapy-induced hand-foot syndrome;Oncology Reviews;2020-05-13